Loading
A phase 3 trial of anlotinib in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting.
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. is a phase 3, randomised interventional study registered as NCT07443397 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 134 participants, started 2025-08-29 and due to reach its primary completion in 2027-08-31. Interventions recorded: Anlotinib; Whole-brain Radiotherapy. Conditions listed: Whole-Brain Radiotherapy. Primary outcome: Intracranial progression-free survival. Lung eligibility wording from the registry: "* Small cell lung cancer confirmed by pathology, with brain metastases diagnosed either at initial presentation or during treatment, and measurable disease according to RECIST criteria". Sites: China. No results are recorded here; the registry entry is the source.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer, IMRT / IGRT (modern external beam) and the tag lung-deep-dive.
Shares Anlotinib, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Small-molecule kinase inhibitors and the tag lung-deep-dive.